Rocket Pharmaceuticals, Inc. (RCKT) stock
RCKTNasdaqPharmaceutical PreparationsFiscal year ends December 31
$2.11+0.00 (0.00%)
Close on Nov 18, 2026Market cap $231.62MP/E –Yield –
Rocket Pharmaceuticals r&d expenses
Research and development expenses are spending on new products and technology.
Rocket Pharmaceuticals's R&D Expenses for the twelve months ending Jun 30, 2026 was $124.37M, down 21.4% year over year. For fiscal 2025 it was $142.02M, down 17.1% from the year before. Over ten years it grew 27.5% a year on average. The highest annual figure on record is $186.34M in fiscal 2023.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $142.02M | -17.1% |
| FY2024 | Dec 31, 2024 | $171.24M | -8.1% |
| FY2023 | Dec 31, 2023 | $186.34M | +12.5% |
| FY2022 | Dec 31, 2022 | $165.57M | +32.0% |
| FY2021 | Dec 31, 2021 | $125.48M | +19.0% |
| FY2020 | Dec 31, 2020 | $105.44M | +82.1% |
| FY2019 | Dec 31, 2019 | $57.91M | +8.7% |
| FY2018 | Dec 31, 2018 | $53.27M | +257.1% |
| FY2017 | Dec 31, 2017 | $14.92M | +148.9% |
| FY2016 | Dec 31, 2016 | $5.99M | -52.3% |
| FY2015 | Dec 31, 2015 | $12.55M | +124.5% |
| FY2014 | Dec 31, 2014 | $5.59M | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $29.50M | -30.9% |
| Q1 FY2026 | Mar 31, 2026 | $31.45M | -12.5% |
| Q4 FY2025 | Dec 31, 2025 | $29.35M | -21.4% |
| Q3 FY2025 | Sep 30, 2025 | $34.07M | -19.5% |
| Q2 FY2025 | Jun 30, 2025 | $42.66M | -8.0% |
| Q1 FY2025 | Mar 31, 2025 | $35.94M | -20.5% |
| Q4 FY2024 | Dec 31, 2024 | $37.36M | -10.5% |
| Q3 FY2024 | Sep 30, 2024 | $42.32M | -9.7% |
| Q2 FY2024 | Jun 30, 2024 | $46.35M | -9.8% |
| Q1 FY2024 | Mar 31, 2024 | $45.23M | -2.5% |
| Q4 FY2023 | Dec 31, 2023 | $41.74M | -16.6% |
| Q3 FY2023 | Sep 30, 2023 | $46.84M | +8.0% |
| Q2 FY2023 | Jun 30, 2023 | $51.38M | +24.2% |
| Q1 FY2023 | Mar 31, 2023 | $46.37M | +50.6% |
| Q4 FY2022 | Dec 31, 2022 | $50.04M | +51.5% |
| Q3 FY2022 | Sep 30, 2022 | $43.38M | +9.5% |
| Q2 FY2022 | Jun 30, 2022 | $41.36M | +68.6% |
| Q1 FY2022 | Mar 31, 2022 | $30.79M | +8.8% |
| Q4 FY2021 | Dec 31, 2021 | $33.02M | -34.1% |
| Q3 FY2021 | Sep 30, 2021 | $39.62M | +82.9% |
| Q2 FY2021 | Jun 30, 2021 | $24.53M | +46.6% |
| Q1 FY2021 | Mar 31, 2021 | $28.31M | +66.9% |
| Q4 FY2020 | Dec 31, 2020 | $50.09M | +259.0% |
| Q3 FY2020 | Sep 30, 2020 | $21.66M | +46.0% |
| Q2 FY2020 | Jun 30, 2020 | $16.73M | +19.6% |
| Q1 FY2020 | Mar 31, 2020 | $16.96M | +12.0% |
| Q4 FY2019 | Dec 31, 2019 | $13.95M | -41.1% |
| Q3 FY2019 | Sep 30, 2019 | $14.83M | +13.5% |
| Q2 FY2019 | Jun 30, 2019 | $13.99M | +29.9% |
| Q1 FY2019 | Mar 31, 2019 | $15.14M | +163.6% |
| Q4 FY2018 | Dec 31, 2018 | $23.68M | +381.5% |
| Q3 FY2018 | Sep 30, 2018 | $13.07M | +167.0% |
| Q2 FY2018 | Jun 30, 2018 | $10.77M | +282.1% |
| Q1 FY2018 | Mar 31, 2018 | $5.74M | +151.3% |
| Q4 FY2017 | Dec 31, 2017 | $4.92M | -48.2% |
| Q3 FY2017 | Sep 30, 2017 | $4.89M | -41.8% |
| Q2 FY2017 | Jun 30, 2017 | $2.82M | – |
| Q1 FY2017 | Mar 31, 2017 | $2.29M | – |
| Q4 FY2016 | Dec 31, 2016 | $9.49M | – |
| Q3 FY2016 | Sep 30, 2016 | $8.41M | – |
See a number that looks wrong?